Bionor Pharma ASA

Type: Company
Name: Bionor Pharma ASA
First reported Apr 11 2014 - Updated Apr 11 2014 - 1 reports

Recently Released Market Study: Hepatitis C - Pipeline Review, H1 2014

Boston, MA -- ( SBWIRE ) -- 04/11/2014 -- Global Markets Direct's, 'Hepatitis C - Pipeline Review, H1 2014', provides an overview of the Hepatitis C's therapeutic pipeline.This report provides comprehensive information on the therapeutic development for ... [Published SBWire - Apr 11 2014]
First reported Apr 01 2014 - Updated Apr 01 2014 - 2 reports

Bionor Pharma Announces Completion of Enrollment of Part A of REDUC Trial

Bionor Pharma ASA announced today the completion of enrollment of patients for part A of the Phase I /II REDUC study. The trial combines Bionor Pharma’s lead vaccine candidate Vacc-4x and the HDAC inhibitor Istodax® (romidepsin). Part A of the study will ... [Published BioPortfolio - Apr 01 2014]
First reported Apr 01 2014 - Updated Apr 01 2014 - 1 reports

HIV Vaccine Market Opportunity & Clinical Pipeline Analysis

/PRNewswire/ --Research and Markets (http://www.researchandmarkets.com/research/hnfpj3/hiv_vaccine) has announced the addition of the " " report to their offering.Sponsored by: Ever since HIV was identified as the cause for AIDS 30 years ago, the HIV ... [Published TickerTech.com - Apr 01 2014]
First reported Mar 28 2014 - Updated Mar 28 2014 - 1 reports

Bionor Pharma says results from Vacc-4x Phase II Reboost trial reconfirms 2010 study

6:00am GMTBionor Pharma ASA:Says Phase II Therapeutic HIV Vaccine Vacc-4x, reboost trial, reconfirms 2010 study.The trial explored the effects of Vacc-4x revaccination or reboosting of HIV infected patients that participated in the 2010 Phase II study.Says ... [Published Reuters UK - Mar 28 2014]
First reported Feb 11 2014 - Updated Feb 11 2014 - 1 reports

Bionor Pharma's Phase II Vacc-4x Data Published in the Lancet Infectious Diseases

Therapeutic HIV Vaccine, Vacc-4x, Reduced Viral Load in HIV Patients Compared to Placebo in Largest Randomized, Placebo-Controlled Study of Its Kind in Recent History, Published in Lancet Infectious Diseases ... [Published Marketwire - Breaking News Releases - Feb 11 2014]

Quotes

Original Article: NEXT ARTICLE More From BioPortfolio on "Bionor Pharma Announces Completion of Enrollment of Part A of REDUC Trial"

More Content

All (6) | News (5) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Recently Released Market Study: Hepatitis C - P... [Published SBWire - Apr 11 2014]
Bionor Pharma Announces Completion of Enrollmen... [Published BioPortfolio - Apr 01 2014]
Bionor Pharma Announces Completion of Enrollmen... [Published Noodls - Apr 01 2014]
HIV Vaccine Market Opportunity & Clinical Pipel... [Published TickerTech.com - Apr 01 2014]
Bionor Pharma says results from Vacc-4x Phase I... [Published Reuters UK - Mar 28 2014]
Bionor Pharma's Phase II Vacc-4x Data Published... [Published Marketwire - Breaking News Releases - Feb 11 2014]
1
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Bionor Pharma's Phase II Vacc-4x Data Published... [Published Marketwire - Breaking News Releases - Feb 11 2014]
Therapeutic HIV Vaccine, Vacc-4x, Reduced Viral Load in HIV Patients Compared to Placebo in Largest Randomized, Placebo-Controlled Study of Its Kind in Recent History, Published in Lancet Infectious Diseases ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.